We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: schizophrenia
MedXY News
EnglishTag

schizophrenia

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Relapse Trajectories and Antipsychotic Discontinuation in Schizophrenia: Insights from a Meta-Analysis and Contemporary Evidence
Clinical Updatespaliperidoneantipsychotic discontinuation

Relapse Trajectories and Antipsychotic Discontinuation in Schizophrenia: Insights from a Meta-Analysis and Contemporary Evidence

By MedXY|Aug 27, 2026

This review synthesizes a meta-analysis of relapse trajectories following paliperidone discontinuation with evidence on antipsychotic maintenance and discontinuation strategies, highlighting individualized risk stratification and clinical i

Time-Dependent Symptom Improvement in Schizophrenia: Insights from Six Antipsychotic Trials
newsschizophrenia
antipsychotic treatment

Time-Dependent Symptom Improvement in Schizophrenia: Insights from Six Antipsychotic Trials

By MedXY|Aug 5, 2026

This analysis of six antipsychotic trials reveals distinct temporal patterns in the improvement of schizophrenia symptom domains, with hostility and excitement responding fastest and negative and cognitive symptoms improving more slowly, gu

Psychiatryschizophreniadopamine

Pluralistic Model Proposed for Schizophrenia Spectrum: Beyond Dopamine

By MedXY|Jul 24, 2026

A new narrative review synthesizing evidence from 1980 to 2025 argues that schizophrenia spectrum disorders cannot be explained solely by dopaminergic dysfunction. The authors propose a pluralistic model involving multiple neurochemical and cellular processes, with implications for treatment development and biomarker-based stratification.

LB-102 in Acute Schizophrenia: A Promising Benzamide Antipsychotic with Demonstrated Efficacy and Safety
newsantipsychotic efficacyclinical trial

LB-102 in Acute Schizophrenia: A Promising Benzamide Antipsychotic with Demonstrated Efficacy and Safety

By MedXY|Jul 17, 2026

The phase 2 NOVA1 trial demonstrates that LB-102 significantly improves acute schizophrenia symptoms with a favorable safety profile, supporting its potential as a novel treatment option.

Serial Dependence in Working Memory Distinguishes Schizophrenia From Bipolar Disorder With Psychosis
newsbipolar disorderschizophrenia

Serial Dependence in Working Memory Distinguishes Schizophrenia From Bipolar Disorder With Psychosis

By MedXY|Jun 9, 2026

A multisite case-control study found repulsive serial bias in schizophrenia, attractive bias in healthy controls, and mixed patterns in bipolar disorder, supporting serial dependence as a potential cognitive biomarker across the psychosis s

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed
newscancer disparitieslung cancer

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed

By MedXY|May 29, 2026

A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
Diabetes & Endocrinologyantipsychoticsinsulin sensitivity

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

By MedXY|May 26, 2026

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antip

Patient-Derived Neuronal Synapse Deficits Predict Brain Network Abnormalities and Cognitive Impairment in Schizophrenia
NeurologycognitioniPSC

Patient-Derived Neuronal Synapse Deficits Predict Brain Network Abnormalities and Cognitive Impairment in Schizophrenia

By MedXY|May 15, 2026

A multimodal translational study links genetically driven synaptic deficits in patient-derived neurons to cortical structure, electrophysiology, and cognition in schizophrenia, supporting biologically informed stratification of cognitive im

Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia
newsantipsychoticsmeta-analysis

Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia

By MedXY|Mar 6, 2026

This landmark network meta-analysis of 438 RCTs evaluates 24 antipsychotics, revealing clozapine as the most effective while highlighting the novel muscarinic agonist xanomeline-trospium. The study emphasizes clinically relevant efficacy di

Beyond Dopamine Blocking: Network Meta-Analysis Redefines Efficacy and Tolerability Hierarchies in Acute Schizophrenia
newsantipsychoticsNetwork meta-analysis

Beyond Dopamine Blocking: Network Meta-Analysis Redefines Efficacy and Tolerability Hierarchies in Acute Schizophrenia

By MedXY|Mar 6, 2026

A landmark network meta- **Developing Article Components** I’m now diving deep into the content, focusing on fleshing out each section. The Highlight section’s first drafts are complete. I’m incorporating the study’s

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial
Diabetes & Endocrinologycardiometabolic riskGLP-1 receptor agonists

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial

By MedXY|Feb 11, 2026

A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentia

Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation
newsmeta-analysispsychosocial interventions

Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation

By MedXY|Feb 5, 2026

A comprehensive meta-analysis in JAMA Psychiatry reveals that current psychosocial interventions for schizophrenia and co-occurring substance use disorders offer negligible impact on symptoms and no significant effect on substance use reduc

Glutamate Surges in Early Psychosis: Why Timing Matters for Targeted Therapeutics
newsMagnetic Resonance SpectroscopyPsychosis

Glutamate Surges in Early Psychosis: Why Timing Matters for Targeted Therapeutics

By MedXY|Jan 25, 2026

A cross-sectional study of never-medicated individuals reveals that elevated medial prefrontal cortex glutamate levels are specific to the first episode of psychosis and correlate with cognitive deficits, suggesting a critical window for gl

Processing Speed as a Core Endophenotype: New Evidence from a 115-Study Meta-Analysis in Schizophrenia
newsmeta-analysisNeurocognition

Processing Speed as a Core Endophenotype: New Evidence from a 115-Study Meta-Analysis in Schizophrenia

By MedXY|Dec 23, 2025

A comprehensive meta-analysis involving over 10,000 patients reveals that processing speed impairment is a profound and central deficit in schizophrenia, showing an effect size of -1.52 and playing a critical role in overall cognitive dysfu

Elevated Serotonin Release in Schizophrenia: New Insights Into Negative Symptom Pathophysiology
NeurologyNeuroimagingschizophrenia

Elevated Serotonin Release in Schizophrenia: New Insights Into Negative Symptom Pathophysiology

By MedXY|Dec 17, 2025

A PET imaging study reveals increased frontal serotonin release in schizophrenia, particularly in deficit type, tied to worse negative symptoms.

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS
newsclinical trialscognitive impairment

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

By MedXY|Nov 30, 2025

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological chall

Reduced Brain Iron Linked to Striatal Hyperdopaminergia in Schizophrenia: Insights from QSM MRI and PET Imaging
Neurologybrain ironquantitative susceptibility mapping

Reduced Brain Iron Linked to Striatal Hyperdopaminergia in Schizophrenia: Insights from QSM MRI and PET Imaging

By MedXY|Oct 30, 2025

This study reveals that lower brain iron levels in the substantia nigra-ventral tegmental area are associated with elevated striatal dopamine synthesis in schizophrenia, highlighting a potential new target for therapeutic intervention.

Unveiling the Iron-Dopamine Link in Schizophrenia: Insights from QSM MRI and PET Imaging
newsbrain ironquantitative susceptibility mapping

Unveiling the Iron-Dopamine Link in Schizophrenia: Insights from QSM MRI and PET Imaging

By MedXY|Oct 30, 2025

This study reveals reduced brain iron in the substantia nigra-ventral tegmental area correlating with increased striatal dopamine synthesis in schizophrenia, suggesting novel neurobiological mechanisms and potential therapeutic targets.

Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care
newsConsensusrelapse

Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care

By MedXY|Oct 30, 2025

An international expert consensus offers standardized, operational criteria for defining relapse in schizophrenia to reduce study heterogeneity, improve research comparability, and guide clinical reporting.

Comparative Efficacy and Tolerability of Seven Antipsychotics in Acute Schizophrenia: Insights from a Large Multicenter Randomized Trial
newsantipsychoticsefficacy

Comparative Efficacy and Tolerability of Seven Antipsychotics in Acute Schizophrenia: Insights from a Large Multicenter Randomized Trial

By MedXY|Oct 29, 2025

A multicenter randomized trial comparing seven antipsychotics in acute schizophrenia shows olanzapine and risperidone outperform several agents in efficacy but differ markedly in side effects, clarifying treatment choices.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities